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Abstract 
Aim: To summarize the prevalence, frequency and comparative value of information on the 
adverse events of healthcare interventions from user comments and videos in social media.  
Methods: Systematic review of assessments of the prevalence or type of information on 
adverse events in social media. 16 databases and two internet search engines were searched in 
addition to handsearching, reference checking, and contacting experts. The results were sifted 
independently by two researchers. Data extraction and quality assessment were carried out by 
one researcher and checked by a second. The quality assessment tool was devised in-house 
and a narrative synthesis of the results followed. 
Results: From 3064 records, 51 studies met the inclusion criteria.  The studies assessed over 
174 social media sites with discussion forums (70%) being the most popular. The overall 
prevalence of adverse events reports in social media varied from 0.2% to 8% of posts.  
29 studies compared the results from searching social media to using other data sources to 
identify adverse events. There was general agreement that a higher frequency of adverse 
events was found in social media and that this was particularly true for ‘symptom’ related and 
‘mild’ adverse events.  
Those adverse events that were under-represented in social media were laboratory-based and 
serious adverse events. 
Conclusions: Reports of adverse events are identifiable within social media. However, there 
is considerable heterogeneity in the frequency and type of events reported, and the reliability 
or validity of the data has not been thoroughly evaluated. 
 
What is known about this subject 
Social media are commonly used to discuss health issues, including adverse events. 
Social media are increasingly being used as a research tool. 
Techniques have been developed to identify adverse events on social media. 
 
What this study adds 
The prevalence of adverse events reports on social media varies from 0.2% to 8% of posts. 
‘Mild’ and ‘symptom-related’ adverse events are over-represented in social media and 
‘laboratory test abnormalities and ‘serious’ adverse events are under-represented compared to 
other data sources. 
The question as to whether searching social media for adverse events data is a valuable use of 
resources resulting in improved patient outcomes remains unanswered. A cost-effectiveness 
analysis of all pharmacovigilance systems, including social media is urgently required. 
 
Introduction 
Social media are commonly used to discuss health issues. 80% of internet users have 
searched online for health information and 34% have read someone else’s commentary about 
health or medical issues in the last 12 months (1). 
 
Given these figures, it is unsurprising that social media have been discovered as a research 
tool. There is substantial literature on extracting information from social media to monitor 
disease outbreaks (2-15), health behaviors (16-19), and patient views (20-26). 
  
Many patients choose online communities to discuss adverse effects of treatments, 
particularly drug interventions. This generates a large volume of unsolicited and up-to-date 
information. It has been suggested that by monitoring social media it would now take only 
five to seven days to be aware of the Thalidomide disaster (27). Despite public availability of 
these data, their appropriate role in pharmacovigilance has not been established nor are they 
routinely used for collecting adverse effects data. 
 
The comparative value of social media in relation to other data sources (such as 
pharmacovigilance systems or clinical trials) is of interest. We need to know how adverse 
events data from social media compares to data from other sources in the type, range, 
frequency and timeliness of adverse events discovered. Information on social media may not 
be easily obtainable from other sources. With multiple questions which need addressing, 
research into the retrieval of information on adverse events from social media is particularly 
timely. 
 
This systematic review summarizes research on, the prevalence, frequency and type of 
adverse events data for healthcare interventions available via social media and on the relative 
value of social media as a source for adverse events data compared to other sources of data. 
  
 
Methods 
The inclusion criteria were broad in order to provide an understanding of the volume and 
quality of the research in this area. 
Inclusion criteria 
The PICO for this systematic review was as follows; 
Population: Any condition or disease type (chronic or acute) in any population  
Intervention(s): Any type of social media , defined as any computer-mediated tools to create, 
share or exchange information, ideas ,pictures or videos in virtual communities and networks 
(such as message boards, social networks, patient forums, Twitter, blogs and Facebook).  
Simple, non-social internet-based interventions (i.e. web 1.0) were excluded. Social media to 
recruit participants to a study or used exclusively by health professionals were excluded. 
Comparators: Any other data source was eligible as a comparator, including no comparator. 
Outcomes: Data on the type, frequency or prevalence of adverse events data were required.  
A broad definition of adverse events was considered incorporating adverse events (where the 
likelihood of causation has not been measured), adverse effects (events likely to be associated 
with the intervention but can only be detected via laboratory tests) or adverse reactions 
(detected via signs and symptoms experienced by the patient). Any healthcare interventions 
were eligible.  
Study Design: Any type of assessment was included.  
 
Exclusion criteria 
Population: None excluded 
Inervention(s): Simple, non-social internet-based interventions (i.e. web 1.0) were excluded. 
Social media to recruit participants to a study or used exclusively by health professionals 
were excluded. 
Comparators: None excluded 
Outcomes: We were primarily concerned with the properties of interventions under normal 
use. We therefore did not consider papers with the primary aim to assess events such as 
intentional and accidental poisoning (i.e. overdose), drug abuse, errors, or non-compliance. 
Drug-drug interactions were not eligible where they were the primary objective of the paper 
due to the different techniques required in identifying interactions as opposed to adverse 
events. 
Study Design: We excluded discussion papers, examples of posts from social media and 
technological papers which are summarized elsewhere [28].  
 
 
 
Search methods 
16 databases covering a range of topic areas, including health and medical research, nursing, 
information and computer science, and grey literature (i.e. literature that is not formally 
published) were searched (Supplementary Table 1: Sources searched 
).  
 
We undertook other supplementary methods which included searching two internet search 
engines, browsing internet blogs, handsearching journals, newsletters and conference 
proceedings, reference checking all included articles and related systematic reviews, and 
contacting experts in the field. 
 
Search Strategies 
The database search strategies contained two facets – ‘social media’ and ‘adverse events’ 
(Supplementary Box 1: MEDLINE search strategy 
). A date restriction of 1996 onwards was placed on the searches as blogging first began in 
1997. No language restrictions were placed on the searches, although financial and logistical 
restraints did not allow translation from all languages.  
 
Data extraction 
Information was collected on the type of social media used (such as Twitter or Facebook), the 
adverse events and type of interventions searched for, the primary aim of the study as stated 
by the authors and the type and frequency of adverse events data identified. Details of 
comparator sources where noted along with any comparisons of the data collected. Lastly, 
data were extracted on the conclusions of the original investigators. 
 Assessment of methodological quality 
We did not stipulate any restriction on design of the included studies. As there is no relevant 
quality assessment checklist for these type of studies, we designed a bespoke tool based on 
five key areas to reflect potential risks of bias. These five key criteria were: 
 
1. Search strategy to identify posts: How were the posts searched for? Were adequate 
search terms used? Searching social media is difficult due to the unstructured nature 
of the data. In particular, colloquial expressions/informal speech, misspellings, 
nicknames, the use of non-standard abbreviations used, different synonyms and 
different spellings make a comprehensive search impossible. However, attempts 
should be made to include numerous synonyms, spellings etc.. 
 
2. Selection of relevant posts: What methods were used in selecting relevant posts? For 
example, were double screening methods used for manual selection? Were 
computerized methods validated? 
 
3. Definition of a report of an adverse event: Was there a clear definition of what 
constitutes an adverse report? (for example, the Food and Drug Administration (FDA) 
minimum criteria of an identifiable reporter, an identifiable patient, a reaction or 
event, and a suspected medicinal product) 
 
 
4. Duplicate data: Did the researchers measure the amount of duplicate data? Were 
duplicate reports from the same user excluded?  
 
Analysis 
It was anticipated that the included studies would be heterogeneous in nature as methods in 
this area are still under development. A narrative synthesis was therefore used. 
 
Results 
The database and internet searches identified 3045 records, and these results were augmented 
with studies identified from handsearching, reference checking, contacting experts, peer 
reviewers suggestions and studies already known by the authors (Figure 1 and Supplementary 
Table 2: Search results by database). Altogether 51 studies from 64 publications met the 
inclusion criteria  
(Supplementary Table 3: Characteristics of included studies) (28-91). 
There were 180 excluded studies based on the full-text papers (Supplementary Table 4: 
Excluded studies).  
 
Baseline characteristics of studies 
Social media 
Over 174 different social media sites were represented in the 51 studies. 71% (36/51) of the 
studies examined discussion forums, 10 looked at Twitter, five at Facebook, four at blogs, 
three at YouTube, one at RxISK and one at Treato (Figure 2). Three studies did not report the 
websites searched and seven studies looked at more than one type of social media.  
Discussion forums 
Of the 36 studies that looked at discussion forums six did not specify the forums searched, 
and one gave an incomplete listing. The most popular named forums were DailyStrength (six 
studies), WebMD (five studies), AskaPatient (five studies), MedHelp (four studies), 
ehealthforum (three studies), healthboards.com (three studies), PatientsLikeMe (three 
studies), and revolutionhealth (three studies).  
 
The most popular disease specific patient forums were for cancer (five studies), depression 
(three studies), heart conditions (two studies) and diabetes (two studies). The number of 
forums searched ranged from one to 24, with an average of four forums searched in each 
study.  
 
Interventions 
Most studies looked at drug interventions (86%, 44/51), with only three looking at surgery 
(one with YouTube), two limiting by illness, and two looking for a medical device (both with 
YouTube). Of those studies that included drug interventions most assessed multiple drugs 
(84%, 37/44) whilst those studies assessing surgery or a medical device only evaluated one 
intervention.   
 
Adverse events 
90% (46/51) of the papers looked for any adverse events whilst only 10% (5/51) specified the 
adverse events they were looking for (withdrawal symptoms, SJS/TEN, fatal skin 
reactions/hypersensitivity, pain and sexual dysfunction).  
 
Study validity 
A summary of the quality assessment of the 51 included studies is contained 
inSupplementary Table 5: Quality assessment of included studies. 
Search strategy to identify posts 
18 studies reported using a search strategy to identify the posts for sifting, 11 browsed a set of 
posts, 12 used some form of automation with a dictionary or lexicon to identify terms and 10 
studies did not report how posts were retrieved.  
 
Due to poor reporting it was difficult to ascertain the number of studies which conducted an 
adequate search strategy (for example, with an adequate range of synonyms, abbreviations 
and spellings) to identify a comprehensive or representative sample of posts from social 
media. Where search strategies were reported none could be considered comprehensive or 
highly sensitive on par with search strategies used in systematic reviews.  
 
Of the 11 studies which simply browsed posts, five were browsed by at least two researchers, 
and in six cases it was unclear.  
 
In the 12 studies which used medical dictionaries – all used multiple dictionaries and some 
adjusted them for the purpose of their research. With social media the use of colloquial terms 
is essential for an adequate search; this was recognized by eight of the 12 studies which either 
incorporated Consumer Health Vocabulary (CHV) or added their own informal terms.  
 
Selection of relevant posts 
Methods used to select relevant posts varied between a solely manual approach (22 studies) 
to the use of automation (12 studies), with 17 studies not reporting on the methods used. Most 
studies which used a manual approach used more than one researcher to select relevant posts 
(82%, 18/22); only two studies reported using only one researcher while two studies did not 
report the number of researchers.  Automated methods are much more difficult to quality 
assess given the level of reporting. In addition, no common evaluation approach for 
automated methods exists and researchers design their own evaluation approaches (92). In 
this review, some studies used a manual check to verify results (for example, by comparing to 
manually annotated records) whereas others compared the results to known adverse effects 
often referred to as a ‘gold standard’ (identified from sources such as drug labels, 
pharmacovigilance or the published literature). 
 
Definition of a report of an adverse event 
The majority of the studies did not stipulate a clear definition of what constitutes an adverse 
report (76%, 39/51). However, seven studies stated that co-occurrence of a term for the drug 
and a term for an adverse event in the same post or in close proximity to each other were 
required for an adverse event report (four of these seven studies also carried out some form of 
manual checking). Five studies used the Food and Drug Administration (FDA) minimum 
criteria of; an identifiable reporter, an identifiable patient, a reaction or event, and a suspected 
medicinal product. The definition of an identifiable reporter varied – some studies accepted 
emails or screen names whereas others required full verified details. 
 
In general, the included studies did not say how much clinical information was available in 
the media postings, or whether causality assessment (such as a Naranjo score) could have 
been performed (however difficult) to determine the likelihood of it being a genuine adverse 
effect/reaction. 
 
 
Duplicate data 
Only six studies reported that they used any measures to exclude duplicate reports. Yet 23 
studies included more than one social media site – in these instances multiple posting may be 
a particularly pressing issue.  
 
Primary aim of the included studies 
For the majority of the studies the primary aim was an assessment of the value of social 
media as an information source on adverse events, either in terms of patient experiences 
(such as, impact of adverse events on patients’ lives and feelings), or the type  or frequency 
of adverse events reports. 22% (11/51) of studies had a primary aim of developing methods 
used to mine social media for adverse events data but also presented their search results (31, 
44, 46, 50, 54-56, 65, 78, 81-84, 91).    
Frequency or prevalence of adverse events 
25 studies reported the frequency of reports of adverse events on social media. Although 
ideally the denominator should have been the total number of posts within the specified time 
frame, often a subset of posts or threads related to the intervention or illness were used. The 
variation in adverse event report frequency in social media was therefore wide ranging from 
0.02% to 78% (Table 1). Obviously studies which calculated the percentage of adverse events 
posts as a proportion of all social media posts reported a lower prevalence than those with 
analysis restricted to intervention-related posts. However, there were clear differences 
between some of the types of social media. For example, the highest percentage of adverse 
event information was identified from YouTube videos, and disease specific forums generally 
had a higher frequency of adverse events than general health forums.  
 
Comparisons against other data sources  
The majority of the studies (58%, 29/51) compared the data retrieved from social media to 
some other source of information.  The most common comparator was to pharmacovigilance 
data (16 studies), followed by published trials (8 studies) (Table 2).  
 
Comparisons were conducted either in terms of the list of adverse events compiled from 
either source (31, 35, 40, 45, 46, 50, 52, 54, 76, 84), a brief narrative comparison (30, 58, 72), 
a crude comparison of the number of studies and the number of posts (49) or some sort of 
comparison of frequency – either by a rank order (34, 35, 37, 41, 42, 87), by the percentage 
of adverse events posts (36, 53, 55, 63, 64, 68, 69), or by number of adverse event reports 
(56, 62, 78).   
 
There was general agreement that there is concordance overall between adverse events 
mentioned in social media and those already documented in other sources (such as drug 
labels or published trials). However, only seven studies reported on the actual percentage of 
adverse events identified in social media that are already documented elsewhere, this ranged 
from 57% to 99% (Table 2).  
 
Those studies which compared the number of reports of specific named adverse events from 
social media to reports for the same adverse events from other sources generally agreed that 
the level of reporting in social media was much higher (34, 36, 42, 48, 51, 53, 58, 78).   
 
More rapid identification of AEs compared to other data sources 
Only one study compared the timeliness of identifying adverse events from social media with 
other sources. This retrospective study compared the year that eight adverse events would 
have been detected using either social media or pharmacovigilance data (81-83).  This paper 
found that social media detected FDA-alerted adverse events much earlier in six of the eight 
case studies. However, the precision or specificity of using social media was not indicated in 
this paper. This would have been particularly valuable given the potential for false positives 
from the large amount of adverse events reports in social media. 
 
 
Types of adverse events in social media 
Some studies found that whilst some adverse events are over-represented in social media, 
other adverse events are under-represented as compared to events from sources such as 
pharmacovigilance systems, drug labels and the literature (Supplementary Table 6: Type of 
adverse event reported in social media in comparison to other sources).  A higher frequency 
of adverse events in social media than in other sources tended to be reported for ‘‘unpleasant 
symptoms’ or adverse events classified as ‘mild’ (31, 34, 40, 42, 48, 54-56, 58, 62-64, 72, 87, 
88). 
 
Adverse events identified via social media but not documented elsewhere also tended to be 
‘mild’ or related to ‘quality of life’ (31, 34, 42, 51, 55, 87, 88). 
 
Under-represented adverse events on social media in contrast tended to include laboratory 
abnormalities (31) or effects requiring diagnosis from a healthcare professional (54, 72). 
Serious or severe adverse events were also under-represented in social media (31, 40, 55, 56, 
62-64, 72). Severe adverse events were described by the users as ‘severe’ or were events 
requiring immediate clinical intervention (as defined in the papers). 
 
Only three studies found some contradictory evidence of the higher incidence of reporting of 
‘mild’ adverse events in social media. These studies reported a lower incidence of nausea and 
constipation (54), somnolence and dizziness (68), and headaches and nausea (62).  One study 
also found lower rates of subjective adverse events in social media (60) and another reported 
on a laboratory value (high cholesterol) in social media which was not reported in other 
sources (31). 
 
Discussion  
The large number of included and excluded studies in this review demonstrates the high level 
of attention that the utilization of social media for adverse events identification is receiving. 
There were only nine publications in the eight years spanning 2002 to 2010, but there has 
been a rapid increase recently, with 23 articles in 2014 alone. 
 
Despite the disparate nature of the included studies, there are some key findings that merit 
further discussion. Numerous studies confirm that techniques are available to obtain signals 
of adverse events reported in social media. There is general concordance with other sources 
for the majority of adverse events. Social media are able to confirm known adverse 
effects/reactions and highlight novel or rare adverse events for signal generation/hypothesis 
testing, provide more detailed information on patient experiences and may possibly detect 
adverse effects/reactions earlier than pharmacovigilance systems, such as the current FDA 
system. Patients may find it easier to discuss their experience of adverse events on social 
media than to file spontaneous reports with regulatory agencies. 
 
A different emphasis on the type of adverse events reported on social media was identified in 
the studies, which suggested that social media may be a better source for ‘symptom-related’ 
or less ‘serious’ (non-life threatening or not requiring hospitalization) than laboratory test 
abnormalities and ‘serious’ adverse events.   
 
It is unclear though from the included studies whether trawling social media genuinely 
improves upon existing knowledge or would be a worthwhile use of precious resources. This 
stems from important weaknesses in the methodological quality of the included studies, 
which means that robust conclusions cannot be drawn.  
 
The biggest problem (particularly with automated or semi-automated methods) is that the 
purported adverse events may not be adverse events at all. Terms used to describe adverse 
events can also be used for indications of the condition being treated, beneficial effects (i.e. 
sleepiness can be a beneficial effect for someone with insomnia), or may not have been 
experienced by a patient. For example, within statements such as ‘Works to calm mania or 
depression but zonks me and scares me about the diabetes issues reported’ – diabetes is not 
an adverse event but an expressed concern (54). In one of the included studies ‘uterine 
cancer’ co-occurred 374 times with tamoxifen but most of the messages demonstrated only 
anxiety about taking tamoxifen because of this adverse event (31). In most studies attempts 
were made to eliminate false positive posts using algorithms, Natural Language Processing 
(NLP) or manual processes.   
 
Reported abnormalities may have been caused by the disease rather than drug (e.g. 
confounding by indication). Although attempts were made to automatically classify a causal 
relationship it was particularly difficult to distinguish between symptoms that a drug is 
treating and the adverse effects/reactions it causes (69). Also, a major limitation is that the 
included studies did not really look at whether sufficient clinical detail is available to allow 
meaningful interpretation of the social media postings, or whether causality assessment was 
feasible. Although a number of studies acknowledged the potential for spam or non-genuine 
posting, they also recognized the difficulties of verifying posts [29, 31-33, 35, 36, 43, 44, 46, 
48, 50, 52, 53, 60, 61, 66, 71, 72, 77, 84, 86]. Many authors thought that the problem of non-
genuine posts may not be as large a problem as perceived because of site moderators, a lack 
of incentive or lengthy procedures to become a member of the site.  One study found that 
0.5% of posts were being spam and another study found that 6% of Facebook members were 
not real people. 
 
Even if social media contains genuine posts, they may not reflect the true population of 
people who experience adverse events (for example, women and younger people are more 
likely to post on social media) and may be influenced by media report or individual biases.  
 
Some of the included studies reported differences in frequency or type of adverse events in 
comparison to more established data sources. Whether these differences genuinely reflect 
new adverse effects/reactions or more accurate frequencies of adverse effects/reactions is 
unknown as this was not tested or validated in any of the papers. We believe that there is 
currently very little robust data to justify the value of mining social media for previously 
unrecognized signals that might subsequently go on to become validated as genuine adverse 
drug reactions. Hence, we believe in a very cautious approach to social media postings which 
report adverse events that may or may not actually be related to drug therapy. 
 
However, social media can provide more complete information on adverse effects/reactions 
considered important by patients, and aid researchers in understanding patient perceptions 
(32, 33). In one study, the authors proposed that frequency data should not serve as 
prevalence of the adverse effects/reactions but as measure of which symptoms may be the 
most salient to patients on a day-to-day basis (58). Street et al (93) suggested that social 
media can be used to inform Health Technology Assessments of interventions by gaining 
community perspectives, such as acceptability, social impact and potential uptake.  They 
argue that social media can uncover a richer explanation of the issues involved with 
interventions to inform systematic reviews.(93) These conclusions could be relevant to 
reviews which incorporate adverse effects/reactions.  
 
The next step for researchers may be to conduct prospective evaluations on how these data on 
adverse events from social media can give added value, particularly when directly compared 
to standard pharmacovigilance systems. Although many have discussed the value of this type 
of data for pharmacovigilance, the methods to incorporate these data into current systems are 
largely unexplored. In addition the ways in which data from social media can help inform 
primary and secondary research (such as clinical trials and systematic reviews) have not been 
developed (93). Social media could also be explored as a source to identify patient concerns 
on adverse effects/reactions and thus identify priority areas for further research (horizon 
scanning).  
 
Limitations 
There are a number of limitations of this systematic review. First, the difficulties in searching 
for this type of study may have resulted in studies being missed. However, we did attempt to 
compensate for this by including a range of non-databases in addition todatabase sources. 
 There is great scope for selective outcome reporting or publication bias. Researchers may 
selectively choose to submit for publication positive findings about social media, whilst 
negative or null data are not disseminated.  
 
There was a lack of detailed reporting of the output from searching social media in many of 
the studies. Although this was sometimes understandable given that the primary aim of some 
of the studies was the development of methods, this made assessment difficult.  
 
The posts on adverse events may be sensitive to media reports, other people’s posts and to 
other sources of information (such as drug labels) – yet this was rarely discussed.  
 
Lastly, the most relevant question is whether the information from social media will help 
improve clinical practice or protect patients from harm. This was not addressed in any of the 
included studies. 
Conclusions 
The limitations of searching social media for adverse events – such as the difficulties in 
searching, the large volume of irrelevant data, issues surrounding lack of validation, the 
danger of misinformation and duplicate reports were evident.  
 
Although it is difficult to state the prevalence of adverse events reports in social media, it is 
quite apparent that a large volume of real-time, first hand experiences of adverse events are 
posted online. Social media may be a source for novel or rare adverse events and ‘mild’ 
adverse events and for ascertaining patient perspectives. The extent to which researchers 
searching social media for adverse events can lead to patient benefit, however, is unknown. 
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